{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:56:06Z","timestamp":1791831366145,"version":"4.3.4"},"reference-count":27,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2023,11,1]]},"abstract":"Importance<\/jats:title>Clinicians recommend enteric-coated aspirin to decrease gastrointestinal bleeding in secondary prevention of coronary artery disease even though studies suggest platelet inhibition is decreased with enteric-coated vs uncoated aspirin formulations.<\/jats:p><\/jats:sec>Objective<\/jats:title>To assess whether receipt of enteric-coated vs uncoated aspirin is associated with effectiveness or safety outcomes.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This is a post hoc secondary analysis of ADAPTABLE (Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness), a pragmatic study of 15\u202f076 patients with atherosclerotic cardiovascular disease having data in the National Patient-Centered Clinical Research Network. Patients were enrolled from April 19, 2016, through June 30, 2020, and randomly assigned to receive high (325 mg) vs low (81 mg) doses of daily aspirin. The present analysis assessed the effectiveness and safety of enteric-coated vs uncoated aspirin among those participants who reported aspirin formulation at baseline. Data were analyzed from November 11, 2019, to July 3, 2023.<\/jats:p><\/jats:sec>Intervention<\/jats:title>ADAPTABLE participants were regrouped according to aspirin formulation self-reported at baseline, with a median (IQR) follow-up of 26.2 (19.8-35.4) months.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary effectiveness end point was the cumulative incidence of the composite of myocardial infarction, stroke, or death from any cause, and the primary safety end point was major bleeding events (hospitalization for a bleeding event with use of a blood product or intracranial hemorrhage). Cumulative incidence at median follow-up for primary effectiveness and primary safety end points was compared between participants taking enteric-coated or uncoated aspirin using unadjusted and multivariable Cox proportional hazards models. All analyses were conducted for the intention-to-treat population.<\/jats:p><\/jats:sec>Results<\/jats:title>Baseline aspirin formulation used in ADAPTABLE was self-reported for 10\u202f678 participants (median [IQR] age, 68.0 [61.3-73.7] years; 7285 men [68.2%]), of whom 7366 (69.0%) took enteric-coated aspirin and 3312 (31.0%) took uncoated aspirin. No significant difference in effectiveness (adjusted hazard ratio [AHR], 0.94; 95% CI, 0.80-1.09; P<\/jats:italic>\u2009=\u2009.40) or safety (AHR, 0.82; 95% CI, 0.49-1.37; P<\/jats:italic> = .46) outcomes between the enteric-coated aspirin and uncoated aspirin cohorts was found. Within enteric-coated aspirin and uncoated aspirin, aspirin dose had no association with effectiveness (enteric-coated aspirin AHR, 1.13; 95% CI, 0.88-1.45 and uncoated aspirin AHR, 0.99; 95% CI, 0.83-1.18; interaction P<\/jats:italic>\u2009=\u2009.41) or safety (enteric-coated aspirin AHR, 2.37; 95% CI, 1.02-5.50 and uncoated aspirin AHR, 0.89; 95% CI, 0.49-1.64; interaction P<\/jats:italic>\u2009=\u2009.07).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this post hoc secondary analysis of the ADAPTABLE randomized clinical trial, enteric-coated aspirin was not associated with significantly higher risk of myocardial infarction, stroke, or death or with lower bleeding risk compared with uncoated aspirin, regardless of dose, although a reduction in bleeding with enteric-coated aspirin cannot be excluded. More research is needed to confirm whether enteric-coated aspirin formulations or newer formulations will improve outcomes in this population.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT02697916<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamacardio.2023.3364","type":"journal-article","created":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T15:03:14Z","timestamp":1696431794000},"page":"1061","source":"Crossref","is-referenced-by-count":19,"title":["Effectiveness and Safety of Enteric-Coated vs Uncoated Aspirin in Patients With Cardiovascular Disease"],"prefix":"10.1001","volume":"8","author":[{"given":"Amber","family":"Sleem","sequence":"first","affiliation":[{"name":"Department of Medicine, Ochsner Medical Center, New Orleans, Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark B.","family":"Effron","sequence":"additional","affiliation":[{"name":"John Ochsner Heart and Vascular Institute, University of Queensland-Ochsner Clinical School, New Orleans, Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Stebbins","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Wruck","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University, Durham, North Carolina"},{"name":"Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Marquis-Gravel","sequence":"additional","affiliation":[{"name":"Montreal Heart Institute, Montreal, Canada"},{"name":"Department of Medicine, Duke University Health System, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Mu\u00f1oz","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard N.","family":"Re","sequence":"additional","affiliation":[{"name":"Research Division, Ochsner Medical Center, New Orleans, Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Gupta","sequence":"additional","affiliation":[{"name":"University of Kansas Medical Center, Kansas City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl J.","family":"Pepine","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Florida, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep K.","family":"Jain","sequence":"additional","affiliation":[{"name":"Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saket","family":"Girotra","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, University of Texas Southwestern Medical Center, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Whittle","sequence":"additional","affiliation":[{"name":"Department of Medicine, Medical College of Wisconsin, Milwaukee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine P.","family":"Benziger","sequence":"additional","affiliation":[{"name":"Essentia Health Heart and Vascular Center, Duluth, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Farrehi","sequence":"additional","affiliation":[{"name":"University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirk U.","family":"Knowlton","sequence":"additional","affiliation":[{"name":"Intermountain Medical Center Heart Institute, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar S.","family":"Polonsky","sequence":"additional","affiliation":[{"name":"University of Chicago Medicine, Department of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew T.","family":"Roe","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell L.","family":"Rothman","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Harrington","sequence":"additional","affiliation":[{"name":"Department of Medicine, Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Schuyler","family":"Jones","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University, Durham, North Carolina"},{"name":"Department of Medicine, Duke University Health System, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian F.","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University, Durham, North Carolina"},{"name":"Department of Medicine, Duke University Health System, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10","key":"hoi230048r1","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1161\/01.CIR.101.10.1206","article-title":"Aspirin.","volume":"101","author":"Awtry","year":"2000","journal-title":"Circulation"},{"issue":"6","key":"hoi230048r2","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.jacc.2016.11.050","article-title":"Enteric coating and aspirin nonresponsiveness in patients with type 2 diabetes mellitus.","volume":"69","author":"Bhatt","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"hoi230048r3","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/bcp.2011.72.issue-4","article-title":"Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy.","volume":"72","author":"Warner","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"hoi230048r4","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1161\/01.STR.0000174189.81153.85","article-title":"Risk of hemorrhagic stroke with aspirin use: an update.","volume":"36","author":"Gorelick","year":"2005","journal-title":"Stroke"},{"issue":"8195 pt 1","key":"hoi230048r5","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S0140-6736(80)90282-2","article-title":"Comparison of the effects of regular and enteric-coated aspirin on gastroduodenal mucosa of man.","volume":"2","author":"Hoftiezer","year":"1980","journal-title":"Lancet"},{"issue":"9039","key":"hoi230048r6","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/S0140-6736(96)01254-8","article-title":"Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product.","volume":"348","author":"Kelly","year":"1996","journal-title":"Lancet"},{"key":"hoi230048r7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1472-6904-1-1","article-title":"Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations.","volume":"1","author":"de Abajo","year":"2001","journal-title":"BMC Clin Pharmacol"},{"issue":"4","key":"hoi230048r8","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1510\/icvts.2007.155788","article-title":"Does enteric-coated aspirin result in a lower incidence of gastrointestinal complications compared to normal aspirin?","volume":"6","author":"Walker","year":"2007","journal-title":"Interact Cardiovasc Thorac Surg"},{"issue":"5","key":"hoi230048r9","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1046\/j.0306-5251.2001.01476.x","article-title":"Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies.","volume":"52","author":"Garc\u00eda Rodr\u00edguez","year":"2001","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"hoi230048r10","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1161\/CIRCULATIONAHA.112.117283","article-title":"Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin.","volume":"127","author":"Grosser","year":"2013","journal-title":"Circulation"},{"issue":"9049","key":"hoi230048r11","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S0140-6736(05)65056-8","article-title":"Gastric safety and enteric-coated aspirin.","volume":"349","author":"Guslandi","year":"1997","journal-title":"Lancet"},{"issue":"3","key":"hoi230048r12","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/bcpt.2015.116.issue-3","article-title":"Enteric coating can lead to reduced antiplatelet effect of low-dose acetylsalicylic acid.","volume":"116","author":"Haastrup","year":"2015","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"7","key":"hoi230048r13","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/j.jacc.2005.06.058","article-title":"Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease.","volume":"46","author":"Maree","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"hoi230048r14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/bdd.v4:1","article-title":"Human platelet response to three salicylate dosage forms.","volume":"4","author":"Thiessen","year":"1983","journal-title":"Biopharm Drug Dispos"},{"issue":"21","key":"hoi230048r15","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1056\/NEJMoa2102137","article-title":"Comparative effectiveness of aspirin dosing in cardiovascular disease.","volume":"384","author":"Jones","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"hoi230048r16","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1001\/jamacardio.2020.0116","article-title":"Rationale and design of the aspirin dosing-a patient-centric trial assessing benefits and long-term effectiveness (ADAPTABLE) trial.","volume":"5","author":"Marquis-Gravel","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"12","key":"hoi230048r17","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.121.008190","article-title":"Validation of cardiovascular end points ascertainment leveraging multisource electronic health records harmonized into a common data model in the ADAPTABLE randomized clinical trial.","volume":"14","author":"Marquis-Gravel","year":"2021","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"8","key":"hoi230048r18","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1161\/01.STR.0000231683.43347.ec","article-title":"Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers.","volume":"37","author":"Cox","year":"2006","journal-title":"Stroke"},{"issue":"10","key":"hoi230048r19","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1111\/jphp.12777","article-title":"Assessing the influence of media composition and ionic strength on drug release from commercial immediate-release and enteric-coated aspirin tablets.","volume":"69","author":"Karkossa","year":"2017","journal-title":"J Pharm Pharmacol"},{"key":"hoi230048r20","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0b013e3181af6d9c"},{"key":"hoi230048r21"},{"issue":"1","key":"hoi230048r22","first-page":"26","article-title":"A comparison of enteric-coated aspirin granules with plain and buffered aspirin: a report of two studies.","volume":"81","author":"Petroski","year":"1986","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"hoi230048r23","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/bcp.1991.32.issue-1","article-title":"Aspirin-induced gastric mucosal damage: prevention by enteric-coating and relation to prostaglandin synthesis.","volume":"32","author":"Hawthorne","year":"1991","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"hoi230048r24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0160046","article-title":"Bleeding risk with long-term low-dose aspirin: a systematic review of observational studies.","volume":"11","author":"Garc\u00eda Rodr\u00edguez","year":"2016","journal-title":"PLoS One"},{"issue":"7","key":"hoi230048r25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0131558","article-title":"PPI versus histamine H2 receptor antagonists for prevention of upper gastrointestinal injury associated with low-dose aspirin: systematic review and meta-analysis.","volume":"10","author":"Mo","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"hoi230048r26","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1161\/CIRCULATIONAHA.114.014992","article-title":"Association of discharge aspirin dose with outcomes after acute myocardial infarction: insights from the treatment with ADP receptor inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) study.","volume":"132","author":"Xian","year":"2015","journal-title":"Circulation"},{"key":"hoi230048r27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909475"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2809795\/jamacardiology_sleem_2023_oi_230048_1698258691.80017.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T16:05:47Z","timestamp":1699459547000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2809795"}},"subtitle":["A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2023,11,1]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2023.3364","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,1]]}}}